The final estimated pCR rates were 44% vs. 17%, 30% vs. 13%, and 60% vs. 22% for pembrolizumab vs. neoadjuvant chemotherapy control in ERBB2-, HR+/ERBB2-, and TNBC, respectively, suggesting that checkpoint inhibition in early-stage, high-risk, and ERBB2- breast cancer is highly likely to be successful in a phase III trial [242]. The gene discussed is ERBB2; the disease is breast cancer.